Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.45 |
| ▸ | PNMT | P11086 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 3/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CD38 | P28907 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | HTR2B | P41595 | 2/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL856873 | 0.86 | TAAR1 (0.43) | TAAR1PNMTGAADPP4BACE1 | |
| SCHEMBL16812305 | 0.82 | TAAR1 (0.45) | TAAR1PNMTGAADPP4BACE1 | |
| SCHEMBL1196554 | 0.82 | TAAR1 (0.45) | TAAR1PNMTGAADPP4BACE1 | |
| SCHEMBL1765193 | 0.80 | PNMT (0.48) | TAAR1PNMTDPP4CYP3A4HTR2A | |
| SCHEMBL27846447 | 0.80 | PNMT (0.45) | TAAR1PNMTDPP4 | |
| SCHEMBL856367 | 0.78 | P2RX7 (0.40) | TAAR1CYP3A4CD38HTR2AHTR2C | |
| SCHEMBL6072548 | 0.77 | TAAR1 (0.36) | TAAR1GAABACE1CYP3A4CD38 | |
| SCHEMBL4120436 | 0.77 | TAAR1 (0.36) | TAAR1GAABACE1CYP3A4CD38 | |
| SCHEMBL6072587 | 0.77 | TAAR1 (0.41) | TAAR1GAABACE1CYP3A4CD38 | |
| SCHEMBL752405 | 0.77 | TAAR1 (0.36) | TAAR1GAABACE1CYP3A4CD38 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3008045-B1 | ANTIBACTERIAL THIAZOLECARBOXYLIC ACIDS | ANTABIO SAS (FR) | 2018-05-09 | — | — | EP | disclosed |
| EP-2884977-B1 | N-ALKYLATED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME (US) | 2017-10-11 | — | — | EP | disclosed |
| CN-102753538-B | Sultam derivatives | HOFFMANN LA ROCHE | 2015-04-08 | — | — | CN | disclosed |
| EP-2504324-B1 | SULTAM DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2015-02-25 | — | — | EP | disclosed |
| US-8314250-B2 | Sultam derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-11-20 | — | — | US | disclosed |
| EP-2504324-A1 | SULTAM DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-10-03 | — | — | EP | disclosed |
| WO-2011064141-A1 | SULTAM DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-03 | — | — | WO | disclosed |
| US-20110124686-A1 | SULTAM DERIVATIVES | ANDERSON KEVIN W | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124686-A1 | SULTAM DERIVATIVES | SULT1A1, SULT2A1, SULT1E1 | TAAR1 2713/4885PNMT 355/4885GAA 1228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.